Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients

被引：17

作者：

Blazer, Ashira ^{[1
]}

Wang, Binhuan ^{[2
]}

Simpson, Danny ^{[3
]}

Kirchhoff, Tomas ^{[3
]}

Heffron, Sean ^{[4
]}

Clancy, Robert M. ^{[1
]}

Heguy, Adriana ^{[5
]}

Ray, Karina ^{[5
]}

Snuderl, Matija ^{[6
]}

Buyon, Jill P. ^{[1
]}

机构：

[1] NYU, Sch Med, Dept Med, Div Rheumatol, New York, NY 10003 USA

[2] NYU, Sch Med, Dept Populat Hlth, Div Biostat, New York, NY USA

[3] NYU, Sch Med, Dept Populat Hlth, Div Genom, New York, NY USA

[4] NYU, Sch Med, Dept Med, Leon H Charney Div Cardiol, New York, NY USA

[5] NYU, Sch Med, Genome Technol Ctr, New York, NY USA

[6] NYU, Sch Med, Dept Pathol & Neurol, New York, NY USA

来源：

PLOS ONE | 2017年 / 12卷 / 08期

关键词：

INTERNATIONAL COLLABORATING CLINICS; CARDIOVASCULAR-DISEASE; KIDNEY-DISEASE; APOL1; CYTOTOXICITY; NEPHROPATHY; PROTEIN; CLASSIFICATION; LOCALIZATION; RECEPTOR;

D O I：

10.1371/journal.pone.0182483

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Objective Atherosclerosis is exaggerated in African American (AA) systemic lupus erythematosus (SLE) patients, with doubled cardiovascular disease (CVD) risk compared to White patients. The extent to which common Apolipoprotein L1 (APOL1) risk alleles (RA) contribute to this trend is unknown. This retrospective cohort study assessed prevalent atherosclerotic disease across APOL1 genotypes in AA SLE patients. Methods One hundred thirteen AA SLE subjects were APOL1-genotyped and stratified as having: zero risk alleles, one risk allele, or two risk alleles. Chart review assessed CVD manifestations including abdominal aortic aneurysm, angina, carotid artery disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, and vascular calcifications. Associations between the genotypes and a composite endpoint defined as one or more CVD manifestations were calculated using logistic regression. Symptomatic atherosclerotic disease, excluding incidental vascular calcifications, was also assessed. Results The 0-risk-allele, 1-risk-allele and 2-risk-allele groups, respectively, comprised 34%, 53%, and 13% of the cohort. Respectively, 13.2%, 41.7%, and 60.0% of the 0-risk allele, 1-risk-allele, and 2-risk-allele groups met the composite endpoint of atherosclerotic CVD (p = 0.001). Adjusting for risk factors-including smoking, ESRD, BMI > 25 and hypertension-we observed an association between carrying one or more RA and atherosclerotic CVD (OR = 7.1; p = 0.002). For symptomatic disease, the OR was 3.5 (p = 0.02). In a time-to-event analysis, the proportion of subjects free from the composite primary endpoint, symptomatic atherosclerotic CVD, was higher in the 0-risk-allele group compared to the 1-risk-allele and 2-risk-allele groups (chi(2) = 6.5; p = 0.04). Conclusions Taken together, the APOL1 RAs associate with prevalent atherosclerotic CVD in this cohort of AA SLE patients, perhaps reflecting a potentiating effect of SLE on APOL1-related cardiovascular phenotypes.

引用

页数：16